Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 26 of 26 publications.

Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Evaluation of physician knowledge of safety and safe use information for intravitreal aflibercept injection in Europe: a second survey of physicians following dissemination of updated risk-minimization materials. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7

Ardeshirrouhanifard S, An H, Goyal RK, Raji M, Segal J, Alexander GC, Mehta HB. Initiation and switching of direct oral anticoagulants among Medicare beneficiaries with cancer and atrial fibrillation. Poster presented at the 2021 American Heart Association, Epidemiology Scientific Session; May 2021. [abstract] Circulation. 2021 May 25; 143(Suppl 1):AP148.

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z

Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9

Abdul-Jawad Altisent O, Puri R, Regueiro A, Chamandi C, Rodriguez-Gabella T, Del Trigo M, Campelo-Parada F, Couture T, Marsal JR, Cote M, Paradis JM, DeLarochellière R, Doyle D, Mohammadi S, Dumont E, Rodes-Cabau J. Predictors and association with clinical outcomes of the changes in exercise capacity after transcatheter aortic valve replacement. Circulation. 2017 Aug 15;136(7):632-43. doi: 10.1161/CIRCULATIONAHA.116.026349

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Ferreira-Gonzalez I, Marsal JR, Ribera A, Permanyer-Miralda G, Garcia-Del Blanco B, Marti G, Cascant P, Martin-Yuste V, Brugaletta S, Sabate M, Alfonso F, Capote ML, De La Torre JM, Ruiz-Lera M, Sanmiguel D, Cardenas M, Pujol B, Baz JA, Iniguez A, Trillo R, Gonzalez-Bejar O, Casanova J, Sanchez-Gila J, Garcia-Dorado D. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010 Sep 7;122(10):1017-25. doi: 10.1161/CIRCULATIONAHA.110.938290

Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002 Jan 1;106(23):2919-24.

Adams MR, Golden DL, Register TC, Anthony MS, Hodgin JB, Williams JK. The atheroprotective effect to dietary soy isoflavones in apolipoprotein E -/- mice requires the presence of estrogen receptor-a. Circulation. 2002;p.106.

Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Evans GE, Liao D. Prospective association between hormone replacement therapy and the QT index. Circulation. 2001;104:II-792.

Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000 Jun 6;101(22):2572-8.

Anthony MS, Clarkson TB, Evans GW. Estrogen-only versus estrogen + progestin replacement therapy: effects on coronary artery atherosclerosis extent and carotid artery intima-media thickness. Presented at the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1, 2000. San Diego, CA. [abstract] Circulation. 2000; 101(6):714.

Williams K, Anthony MS, Andersen HL. A comparison of plant and mammalian estrogens on dilator and constrictor responses of atherosclerotic coronary arteries in postmenopausal monkeys. Circulation. 1998 Oct;98(Suppl I):I-463.

Clarkson TB, Anthony MS. Effect of hormone replacement therapy on internal carotid artery atherosclerosis on postmenopausal monkeys. Circulation. 1998;97:830.

Anthony MS, Clarkson TB. Comparison of soy phytoestrogens and conjugated equine estrogens on atherosclerosis progression on postmenopausal monkeys. Presented at the 38th Annual Conference on Cardiovascular Disease Epidemiology and Prevention; March 1998. Sante Fe, NM. [abstract] Circulation. 1998; 97:829.

Williams JK, Sukhova Gk, Anthony MS, Libby P. The cholesterol-lowering independent effects of pravastatin on the artery wall of monkeys. Circulation. 1997;96(Suppl I):I-607.

Anthony MS, Clarkson TB, Bullock BC. Soy protein versus soy phytoestrogens (isoflavones) in the prevention of coronary artery atherosclerosis of cynomolgus monkeys. Presented at the 69th Scientific Sessions of the American Heart Association; November 1996. New Orleans, LA. [abstract] Circulation. 1996; 94(Suppl I):I-265.

Moran CM, Fleming AD, Sutherland GR, Anderson T, McDicken WN. An evaluation of the properties of myocardial color Doppler energy mapping using test phantoms. Circulation. 1995 Oct 15;92(8):71.

Kaplan JR, Clarkson TB, Adams MR, Anthony MS, Manuck SB, Morgan TM. Oral contraceptives inhibit atherogenesis in female monkeys at high risk due to social subordination. Circulation. 1995;92(Suppl I):I-627.

Honoré EK, Williams JK, Anthony MS. Enhancement of coronary vasodilation by soy phytoestrogens. Circulation. 1995;92(Suppl I):I-349.

Anthony MS, Burke GL, Hughes CLJr, Clarkson TB. Does soy supplementation improve Coronary Heart Disease (CHD) risk? Presented at the 35th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1995. San Antonio, TX. [abstract] Circulation. 1995; 91:925.

Anthony MS, Clarkson TB, Hughes CL. Plant and mammalian estrogen effects on plasma lipids of female monkeys. Presented at the 67th Annual Scientific Sessions, American Heart Association; November 1994. Dallas, TX. [abstract] Circulation. 1994; 90:I-235.

Anthony MS, Crouse JR. Heterogeneity in plasma lipoprotein response to dietary fish oil. Presented at the 61st Scientific Sessions of the American Heart Association; November 1988. Washington, DC. [abstract] Circulation. 1988; 78(Suppl II):571. Previously presented at the 8th International Symposium on Atherosclerosis.